Vistagen Therapeutics (VTGN) Short Interest Ratio & Short Volume → Trump’s Former Wingman Bets Big on AI (From Banyan Hill Publishing) (Ad) Free VTGN Stock Alerts $4.61 +0.09 (+1.99%) (As of 01:27 PM ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Vistagen Therapeutics Short Interest DataCurrent Short Volume1,180,000 sharesPrevious Short Volume1,290,000 sharesChange Vs. Previous Month-8.53%Dollar Volume Sold Short$5.70 millionShort Interest Ratio / Days to Cover4.6Last Record DateApril 30, 2024Outstanding Shares27,020,000 sharesFloat Size24,300,000 sharesShort Percent of Float4.86%Today's Trading Volume76,090 sharesAverage Trading Volume262,832 sharesToday's Volume Vs. Average29% Short Selling Vistagen Therapeutics ? Sign up to receive the latest short interest report for Vistagen Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatVTGN Short Interest Over TimeVTGN Days to Cover Over TimeVTGN Percentage of Float Shorted Over Time Ad Allegiance GoldDoes this make you sick?The US Dollar Is "Finished" A deteriorating economy, global instability, and a weakened banking system have pushed the U.S. financial system to the brink, imperiling the value of your savings and investments.Get your Free Wealth Protection Kit Vistagen Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/20241,180,000 shares $5.70 million -8.5%4.9%4.6 $4.83 4/15/20241,290,000 shares $6.13 million +0.8%5.3%4.9 $4.75 3/31/20241,280,000 shares $6.76 million -3.8%5.3%4.4 $5.28 3/15/20241,330,000 shares $5.39 million -8.9%5.5%4.7 $4.05 2/29/20241,460,000 shares $7.46 million -15.1%6.0%3.6 $5.11 2/15/20241,720,000 shares $9.32 million +27.4%7.1%4.1 $5.42 Get the Latest News and Ratings for VTGN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Vistagen Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/31/20241,350,000 shares $6.45 million +16.4%5.6%2.6 $4.78 1/15/20241,160,000 shares $6.32 million -28.8%4.8%2.1 $5.45 12/31/20231,630,000 shares $8.38 million +37.0%6.7%2.7 $5.14 12/15/20231,190,000 shares $5.93 million -4.8%4.9%1.8 $4.98 11/30/20231,250,000 shares $4.49 million -21.4%5.1%2.1 $3.59 11/15/20231,590,000 shares $5.23 million +2.6%6.4%2.7 $3.29 10/31/20231,550,000 shares $4.93 million +14.8%7.0%1.4 $3.18 10/15/20231,350,000 shares $4.64 million +61.6%6.1%0.7 $3.44 9/30/2023835,300 shares $4.38 million +16.8%3.5%0.4 $5.24 9/15/2023715,100 shares $4.25 million -31.9%7.7%0.4 $5.95 8/31/20231,050,000 shares $5.60 million -18.0%11.3%0.6 $5.33 8/15/20231,280,000 shares $8.04 million +132.2%13.8%0.7 $6.28 7/31/2023551,300 shares $1.00 million +18.1%7.0%0.4 $1.82 7/15/2023467,000 shares $826,590.00 +36.3%6.0%2.3 $1.77 6/30/2023342,600 shares $640,662.00 -50.2%4.4%1.7 $1.87 6/15/2023687,500 shares $1.43 million +72.2%9.5%3.2 $2.08 5/31/2023399,200 shares $1.70 million -96.8%N/A2.3 $4.26 5/15/202312,450,000 shares $1.75 million -12.0%N/A3.6 $0.14 4/30/202314,150,000 shares $1.98 million -10.6%N/A3 $0.14 4/15/202315,820,000 shares $2.19 million +25.0%N/A2.9 $0.14 3/31/202312,660,000 shares $1.58 million +47.7%N/A2.1 $0.12 3/15/20238,570,000 shares $1.31 million +17.4%N/A1.2 $0.15 2/28/20237,300,000 shares $1.28 million -14.9%N/A1 $0.18 2/15/20238,580,000 shares $1.70 million -15.8%N/A1.1 $0.20 1/31/202310,190,000 shares $2.64 million -17.8%N/A1.5 $0.26 1/15/202312,400,000 shares $1.98 million -19.7%N/A2.1 $0.16 12/30/202215,440,000 shares $1.59 million +36.9%N/A2.5 $0.10 12/15/202211,280,000 shares $1.27 million +24.2%N/A2.1 $0.11 11/30/20229,080,000 shares $1.25 million -1.2%N/A1.7 $0.14 11/15/20229,190,000 shares $1.46 million +13.7%N/A1.5 $0.16 10/31/20228,080,000 shares $1.07 million +26.5%4.6%0.9 $0.13 10/15/20226,390,000 shares $713,124.00 +12.9%3.6%0.5 $0.11 9/30/20225,660,000 shares $860,886.00 +18.4%3.2%0.4 $0.15 9/15/20224,780,000 shares $916,326.00 -12.8%2.7%0.3 $0.19The ONE AI Stock to own now. (It’s not Nvidia.) (Ad)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made …Click here to see the presentation now. VTGN Short Interest - Frequently Asked Questions What is Vistagen Therapeutics' current short interest? Short interest is the volume of Vistagen Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 30th, traders have sold 1,180,000 shares of VTGN short. 4.86% of Vistagen Therapeutics' shares are currently sold short. Learn More on Vistagen Therapeutics' current short interest. What is a good short interest ratio for Vistagen Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. VTGN shares currently have a short interest ratio of 5.0. Learn More on Vistagen Therapeutics's short interest ratio. What is a good short interest percentage for Vistagen Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 4.86% of Vistagen Therapeutics' floating shares are currently sold short. Is Vistagen Therapeutics' short interest increasing or decreasing? Vistagen Therapeutics saw a decline in short interest in the month of April. As of April 30th, there was short interest totaling 1,180,000 shares, a decline of 8.5% from the previous total of 1,290,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Vistagen Therapeutics' float size? Vistagen Therapeutics currently has issued a total of 27,020,000 shares. Some of Vistagen Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Vistagen Therapeutics currently has a public float of 24,300,000 shares. How does Vistagen Therapeutics' short interest compare to its competitors? 4.86% of Vistagen Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Vistagen Therapeutics: Abeona Therapeutics Inc (12.94%), Immunic, Inc. (3.13%), Cartesian Therapeutics, Inc. (6.12%), Karyopharm Therapeutics Inc. (14.59%), Coya Therapeutics, Inc. (1.41%), Nuvectis Pharma, Inc. (13.15%), Cellectar Biosciences, Inc. (7.85%), Amylyx Pharmaceuticals, Inc. (18.07%), OptiNose, Inc. (5.24%), Societal CDMO, Inc. (0.00%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Vistagen Therapeutics stock? Short selling VTGN is an investing strategy that aims to generate trading profit from Vistagen Therapeutics as its price is falling. VTGN shares are trading up $0.09 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Vistagen Therapeutics? A short squeeze for Vistagen Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of VTGN, which in turn drives the price of the stock up even further. How often is Vistagen Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including VTGN, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: Abeona Therapeutics Short Interest Immunic Short Interest Cartesian Therapeutics Short Interest Karyopharm Therapeutics Short Interest Coya Therapeutics Short Interest Nuvectis Pharma Short Interest Cellectar Biosciences Short Interest Amylyx Pharmaceuticals Short Interest OptiNose Short Interest Societal CDMO Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:VTGN) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportBill Clinton Backing Biden Replacement???The Freeport SocietyTrump Reveals Conspiracy Behind Fed-Controlled Digital Currency.Monetary GoldForget the “Magnificent 7” Tech Companies, Buy This AI Stock InsteadBanyan Hill PublishingTop 5 Tech Stocks to Buy for 2024Daily Market AlertsTop 5 AI Stocks to Buy for 2024Market Moving TrendsHow to Play the AI and Crypto Markets in One SwingWeiss Ratingsis this a buy and hold stock?Tips4Traders